Moderna and Merck mRNA Melanoma Vaccine Succeeds in Phase 3

Pharmaceutical companies Moderna and Merck announced on Wednesday that their experimental mRNA-based cancer vaccine, designed to target a patient's specific tumor mutations, demonstrated efficacy in a Phase 3 clinical trial for melanoma patients. This development marks a significant milestone, potentially realizing the long-held promise of mRNA technology and personalized medicine in cancer treatment, representing a first success for both therapeutic approaches. The Phase 3 trial enrolled 1,137 participants diagnosed with stage IIB to IV melanoma, all of whom had undergone surgical removal of their tumors prior to entering the study. Participants were randomly assigned in a two-to-one ratio to receive either a combination therapy comprising the individualized mRNA vaccine, known as V940 or mRNA-4157, alongside Merck's established cancer immunotherapy drug Keytruda (pembrolizumab), or to receive Keytruda alone. Both treatment arms involved approximately one year of therapy. The trial employed a placebo-controlled, double-blind design, ensuring that neither the treating physicians nor the patients were aware of the specific treatment assignments to mitigate bias. The primary endpoint of the trial was recurrence-free survival, a critical measure in assessing the vaccine's ability to prevent cancer from returning after surgery. While specific data on the primary endpoint was not immediately disclosed in the announcement, the partners indicated that the combination therapy demonstrated a statistically significant and clinically meaningful benefit compared to Keytruda alone. This trial builds upon earlier Phase 2b study results that showed a similar trend, where the combination of mRNA-4157 and Keytruda reduced the risk of recurrence or death by 44% compared to Keytruda alone in patients with high-risk melanoma. The personalized mRNA vaccine is developed using a patient's tumor biopsy, which is sequenced to identify neoantigens—unique mutations specific to their cancer. This information is then used to create a custom vaccine that trains the patient's immune system to recognize and attack cancer cells expressing these neoantigens. Keytruda, a programmed cell death protein 1 (PD-1) inhibitor, works by blocking the PD-1 pathway, which cancer cells can exploit to evade the immune system. By combining these two modalities, the therapy aims to enhance the body's anti-tumor immune response more effectively. Moderna and Merck plan to discuss the trial results with regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), in the coming months. If approved, this personalized mRNA cancer vaccine would represent a groundbreaking advancement in oncology, offering a new hope for patients with melanoma and potentially paving the way for similar personalized mRNA therapies for other cancer types.